Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53156

language	eng
Author	Kinoshita, Yoshikazu Kato Mototsugu Department of Gastroenterology, National Hospital Organization Hakodate Hospital, Hakodate, Hokkaido, Japan Fujishiro Mitsuhiro Department of Endoscopy and Endoscopic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan Masuyama Hironori Masuyama Gastrointestinal Clinic, Ohtawara, Tochigi, Japan Nakata Ryo Japanese Red Cross Medical Center, Tokyo, Japan Abe Hisanori Arita GI Hospital, Oita, Oita, Japan Kumagai Shinji Nakajima Hospital, Sendai, Miyagi, Japan Fukushima Yasushi Tokyo-Eki Center-Building Clinic, Tokyo, Japan Okubo Yoshiumi Clinical Development Department, EA Pharma Co., Ltd, Tokyo, Japan Hojo Seiichiro Clinical Data Science Department, Eisai Co., Ltd, Tokyo, Japan Kusano Motoyasu Department of Gastroenterology, Gunma University Hospital, Maebashi, Gunma, Japan
Subject	Endoscopy; GERD; Los Angeles Classification; Proton pump inhibitor; Reflux esophagitis
Journal Title	JOURNAL OF GASTROENTEROLOGY
Volume	53
Issue	7
Start Page	834
End Page	844
ISSN	0944-1174
ISSN（Online）	1435-5922
Published Date	2018-07
DOI	10.1007/s00535-017-1417-z
PubMed ID	29188387
Publisher	SPRINGER JAPAN KK
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	This study was funded by Eisai, Co., Ltd., Tokyo, Japan and EA Pharma Co., Ltd., Tokyo, Japan. The writing and preparation of this paper were funded in part by EA Pharma. Writing support was provided by Eisai. Data analyses were undertaken by Eisai.